Medicus Pharma Ltd. (MDCXW) stock
MDCXWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as MDCX
$0.21+0.00 (0.00%)
Close on Oct 30, 2026Market cap $118.78MP/E –Yield –
Medicus Pharma r&d expenses
Research and development expenses are spending on new products and technology.
Medicus Pharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $11.89M, up 121.2% year over year. For fiscal 2025 it was $7.72M, up 118.9% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.72M | +118.9% |
| FY2024 | Dec 31, 2024 | $3.53M | +1722.4% |
| FY2023 | Dec 31, 2023 | $193.58K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $4.91M | +240.9% |
| Q1 FY2026 | Mar 31, 2026 | $2.70M | +34.8% |
| Q4 FY2025 | Dec 31, 2025 | $2.59M | +89.8% |
| Q3 FY2025 | Sep 30, 2025 | $1.68M | +198.6% |
| Q2 FY2025 | Jun 30, 2025 | $1.44M | +12.7% |
| Q1 FY2025 | Mar 31, 2025 | $2.01M | +524.3% |
| Q4 FY2024 | Dec 31, 2024 | $1.37M | – |
| Q3 FY2024 | Sep 30, 2024 | $564.15K | – |
| Q2 FY2024 | Jun 30, 2024 | $1.28M | – |
| Q1 FY2024 | Mar 31, 2024 | $321.38K | – |